

Tablica 11.1. Prvih 30 lijekova prema financijskoj potrošnji izraženo u kunama u 2021. godini, na teret HZZO-a

RBR	ATK	INN	UKUPNI IZNOS
1	J07BX03	cjepivo protiv COVID-19	609.865.974
2	L01XC18	pembrolizumab	318.540.097
3	L01EL01	ibrutinib	145.835.919
4	L01XC03	trastuzumab	137.559.581
5	B01AF01	rivaroksaban	136.796.332
6	L01XC07	bevacizumab	125.966.420
7	V06DX03	namirnice za enteralnu primjenu	121.340.569
8	L01XC13	pertuzumab	119.531.948
9	L01XC32	atezolizumab	101.832.370
10	N05AX13	paliperidon	94.327.066
11	L02BB04	enzalutamid	91.542.195
12	L01XC17	nivolumab	88.339.059
13	J06BA02	imunoglobulini, humani, za i.v. primjenu	87.222.358
14	A02BC02	pantoprazol	86.300.490
15	L01XC24	daratumumab	83.016.092
16	L04AX04	lenalidomid	76.663.762
17	L01EF01	palbociklib	76.318.852
18	L04AA36	okrelizumab	75.008.258
19	L02BX03	abirateron	74.143.694
20	C10AA05	atorvastatin	72.837.818
21	L04AB04	adalimumab	67.373.802
22	C09BX01	perindopril, amlodipin i indapamid	63.905.861
23	B01AF02	apiksaban	62.591.911
24	L01EF02	ribociklib	58.760.718
25	M09AX07	nusinersen	57.856.508
26	B01AE07	dabigatran eteksilat	57.784.289
27	S01XA27	voretigen neparvovek	56.237.430
28	C09DX04	valsartan i sakubitril	55.122.334
29	L04AB02	infliksimumab	53.885.197
30	L01XC02	rituksimumab	51.921.928